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A B S T R A C T   
Glioblastoma is a malignant brain tumour with a median survival of 14.6 months from diagnosis. Despite 
maximal surgical resection and concurrent chemoradiotherapy, reoccurrence is inevitable. To try combating the 
disease at a stage of low residual tumour burden immediately post-surgery, we propose a localised drug delivery 
system comprising of a spray device, bioadhesive hydrogel (pectin) and drug nanocrystals coated with polylactic 
acid-polyethylene glycol (NCPPs), to be administered directly into brain parenchyma adjacent to the surgical 
cavity. We have repurposed pectin for use within the brain, showing in vitro and in vivo biocompatibility, bio- 
adhesion to mammalian brain and gelling at physiological brain calcium concentrations. Etoposide and ola-
parib NCPPs with high drug loading have shown in vitro stability and drug release over 120 h. Pluronic F127 
stabilised NCPPs to ensure successful spraying, as determined by dynamic light scattering and transmission 
electron microscopy. Successful delivery of Cy5-labelled NCPPs was demonstrated in a large ex vivo mammalian 
brain, with NCPP present in the tissue surrounding the resection cavity. Our data collectively demonstrates the 
pre-clinical development of a novel localised delivery device based on a sprayable hydrogel containing thera-
peutic NCPPs, amenable for translation to intracranial surgical resection models for the treatment of malignant 
brain tumours.   
1. Introduction 
Glioblastoma Multiforme (GBM) is a World Health Organisation 
grade IV brain tumour with a dismal 14.6-month average survival [1] 
from diagnosis when patients receive the standard-of-care therapy. This 
comprises of maximal safe surgical resection followed by concurrent 
chemoradiotherapy. Temozolomide (TMZ) is the chemotherapy of 
choice determined by the Stupp protocol [2,3], due to its efficacy against 
GBM, increasing survival times from 12 months (radiotherapy alone) to 
14.6 months [3]; however, the efficacy of TMZ is limited to tumours 
with the O-6-methylguanine-DNA-methyltransferase (MGMT) gene 
promoter methylated. Silencing of the MGMT promoter by methylation 
leads to reduced DNA repair, thus rendering TMZ associated DNA 
damage more efficacious [4]. 
Despite vast amounts of research, the average lifespan of a patient 
diagnosed with GBM has not greatly increased over the years [5,6]. The 
efficacy of systemic chemotherapy is limited in considerable part due to 
the blood brain barrier (BBB), a physiological obstacle which restricts 
molecular therapeutics from being delivered at efficacious concentra-
tions within the microenvironment of residual post-surgical neoplastic 
cells. This has led to considerable research focus into localised drug 
delivery [7,8] and repurposing systemically toxic chemotherapies [9]. 
Moreover, nanotechnology has advanced the field of local drug delivery, 
whereby drugs are encapsulated within a nano-sized carrier to protect 
the chemotherapeutics from rapid degradation within the body, and in 
turn, to protect the brain from drug-associated toxicities. This capability 
for increased half-life of the drug, has enhanced the efficacy of many 
drugs [10]. 
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For the delivery of chemotherapeutics targeting residual cells 
remaining post-surgery, the nanoparticles (NPs) ideally need to diffuse 
through the brain parenchyma, therefore transporting the drug further 
from the administration site than by drug molecule diffusion alone. 
Recent work has explored the effect of NP size on the ability to penetrate 
through brain tissue. One study in mice showed that 40 and 100 nm 
polystyrene (PS) NPs with a dense poly-(ethylene glycol) (PEG) layer, 
rapidly diffused throughout the brain tissue, whereas 200 nm PS-PEG 
NPs did not, when following their fluorescent signals post-intracranial 
injection. Further work showed that these NPs at 114 nm in diameter 
were able to rapidly diffuse through brain tissue [11] and 70 nm poly 
(lactide-co-glycolide) (PLGA)-PEG NPs (encapsulating paclitaxel), 
were able to diffuse 100-fold faster than analogously sized paclitaxel- 
loaded PLGA NPs without a PEG coating [12]. 
For this work, etoposide and olaparib nanocrystals were chosen for 
coating with polylactic acid-polyethylene glycol (PLA-PEG) to create 
nanocrystals coated with PLA-PEG (NCPPs). These chemotherapeutics 
were chosen due to previous work in the group showing efficacy against 
GBM in vivo [13,14]. Etoposide functions by forming a ternary complex 
with DNA and the Topoisomerase II enzyme, which prevents re-ligation 
of the DNA strands, thus causing the strands to break, leading to cell 
death [15]. Whereas olaparib is a poly-ADP ribose polymerase (PARP) 
inhibitor, targeting the PARP enzyme involved in DNA repair. As cancer 
cells rely on this enzyme to catalyse rapid cell division, PARP inhibition 
renders cells more susceptible to DNA damage-induced apoptosis [16]; 
there is also ongoing work to study the radiosensitising ability of the 
drug [17,18]. 
The method used to encapsulate drugs in this study is a novel 
approach whereby a drug ‘nano-crystal’ is formed, which is later coated 
with a polymer layer, generating high drug loaded NPs [19]. The process 
of NP materialisation occurs when the concentration of the molecule in 
solution exceeds that which is soluble; therefore, the molecules nucleate, 
forming small NPs. Following nucleation, the particles grow by a process 
called Ostwald Ripening, whereby smaller, less stable particles resolu-
bilise and attach onto the surface of larger particles, which then coag-
ulate and coalesce [20]. This drug ‘nano-crystal’ can be coated with a 
polymer coating to provide a steric barrier, protecting them from 
aggregating, reducing further increase in NP size and thus increasing 
colloidal stability. This method has been previously reported to coat 
many metal-based NPs [21]. The amphiphilic polymer coating was 
added to these NPs to transfer these hydrophobically capped metal 
nanocrystals from an organic to an aqueous environments and to reduce 
aggregation of the NPs [22,23]. Our study used a PLA-PEG based 
polymer, which was chosen due to the similarity to the formulation used 
for Genexol®, which is approved for use in South Korea. Genexol® uses 
the same polymeric backbone, selected due to the non-immunogenic 
properties of PEG and the biodegradable core-forming PLA [24]. Since 
this was approved, many studies have trialled PLA-PEG NPs in vivo and 
demonstrated biocompatibility [25–27]. 
Just as the NPs described above, many studies have used hydrogels 
or polymers to deliver chemotherapeutics to the target cells [28]. 
However, to date, the only local drug delivery system (DDS) for brain 
tumours which is approved for human use is the Gliadel® Wafer. The 
wafers, loaded with carmustine [29], have significantly increased the 
lifespan of patients by an average of 3.6 months when compared to TMZ 
alone (10 combined trials, n = 379 patients; median survival range 
12.7–21.3 months) [30]. However, these wafers are rigid and do not 
conform to the irregular-shaped surgical cavity walls. This leaves gaps 
between the wafers and brain tissue, reducing effective drug delivery 
[31]. To address this issue, it is hypothesised that a bioadhesive 
hydrogel could prevent wash-away of NPs by the interstitial fluid by 
holding them temporarily in place before the NPs diffuse away. Similar 
drug-loaded bioadhesive hydrogels have been demonstrated in a wide 
range of applications [32–34]. Delivery of this hydrogel via a spray 
device should allow superior conformation to the cavity walls. 
The bioadhesive gel of choice is low methoxyl (LM) pectin. Pectin, 
from citrus fruit peel, is made up of 1–4 linked α-D galacturonic acid 
residues (with varying degrees of methyl esterification (DE)) with a 
small fraction of rhamnose and small side chains from other sugars such 
as L-arabinofuranose and D-galactopyranose [35,36]. Pectin is defined 
as LM when the (DE) is below 50% and these pectin grades tend to form 
gels electrostatically stabilised by divalent ions (e.g. calcium) or other 
cationic species. As a result, pectin remains in solution state until it 
comes into contact with calcium, at which point it forms a gel via the 
‘egg-box model’; one calcium ion can bond with two carboxyl groups on 
two different chains [37], forming an ionic cross-linked gel. 
The brain has an extracellular calcium concentration of between 1.5 
and 2.0 mM [38] and hence, it is predicted that the pectin will form a gel 
structure upon contact with brain tissue. Pectin is used in other appli-
cations in vivo, such as to deliver drugs nasally for breakthrough pain in 
cancer patients [39]. In the past, it has also been trialled as a plasma 
expander for World War 2 [40], with one report stating that no weight 
loss or toxicity was observed in 776 animals when injected with pectin 
every other day for six weeks [41]; therefore we propose its functionality 
and biocompatibility will be ideal for this application. 
In this work we have developed a novel DDS, which comprises of 
highly drug-loaded (etoposide and olaparib) polymeric NCPPs, held 
within a bioadhesive gel and delivered to brain parenchyma adjacent to 
the surgical resection cavity using a spray device. To our knowledge, this 
is the first-time pectin has been delivered to the in vivo brain, and it is the 
first time a spray device has been used to deliver drug-loaded polymeric 
NPs to a surgical resection margin within the brain. We hypothesise that 
this novel DDS will generate a new means of drug delivery into surgical 
resections of GBM and potentially aid increased survival times with 
further research. 
2. Materials 
Materials were purchased from the following: poly(ethylene glycol) 
methyl ether, Mn = 5000; Pluronic F127 (PF127) and hydroxypropyl- 
β-cyclodextrin (HPβCD), (Sigma-Aldrich); DL-LA, 99% (Fisher Scienti-
fic); artificial cerebrospinal fluid (aCSF; Tocris); etoposide and olaparib 
(ApexBio); erlotinib (SelleckChem); Cyanine5 amine (Cy5; Lumiprobe 
Life Science Solutions); RealTime-GloTM MT cell viability assay (Invi-
trogen); AccuGENE® 10 × PBS buffer (VWR); 50–100 μL classic line 
spray devices (horizontal spray) were kindly donated by Aptar Pharma, 
Germany. Low methyl-esterified citrus fruit pectin, P101, P102, P104 
and P105 were kindly donated by CP Kelco, Denmark. 
3. Methods 
3.1. In vitro biocompatibility analysis 
3.1.1. Pectin 
All gels were made in sterile conditions. Briefly, 1 M calcium chloride 
was aliquoted into a 96-well plate and frozen at − 20 ◦C overnight. 
Pectin powder was weighed into a glass vial and PBS was added drop 
wise whilst stirring on a heated magnetic stirrer (Technico) at 70 ◦C. 
Once solubilised, the pectin was transferred onto the frozen calcium and 
the plate left at 37 ◦C overnight to form gels before washing 3x with PBS. 
Gels were made at 50, 100 and 200 µM. For solution state assays, the 
pectin was not mixed with calcium. For astrocytes (#1800, ScienCell), 
the washed pectin gels were incubated in 100 μL astrocyte medium for 
24 h and the medium then transferred onto cells. These cells were 
indirectly cultured with pectin due to issues with co-culture. If gels sit 
directly on top of the cells, they can reduce nutrient flow from the me-
dium to the cells [42]. In addition, they also can remove cells from the 
well when the hydrogel is removed [43]. This resulted in reduced viable 
astrocyte numbers (data not shown); therefore, it was determined that 
indirect culture (i.e. transfer of medium first incubated with gels, into 
cell plates) would show if leached pectin by-products could cause tox-
icities. This method has also been adopted by others culturing sensitive 
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astrocytes with hydrogels; for example, Tate et al. indirectly cultured rat 
astrocytes with methylcellulose-based constructs, with positive results 
[44]. This method was not utilised for U87 cells (discussed below) as 
these cells are not as sensitive to culture as primary human astrocytes; 
therefore, no contact inhibition was seen for U87 cells. For astrocytes, 
the gels were incubated with medium for 24 h to ensure that there was 
enough time for leaching of pectin into the medium, allowing for more 
comparable results. 
Human astrocytes were cultured as per ScienCell guidelines at a 
seeding density of 5000 cells/cm2. Cell viability post-pectin incubation 
was measured using a RealTime-GloTM MT cell viability assay as per 
manufacturer guidelines. Viability was measured via luminescence 
using a Fluostar Omega plate reader (BMG Labtech) at 24, 48 and 72 h 
post pectin medium addition. 
U87 GBM cells (ATCC®) were cultured in DMEM supplemented with 
10% FBS (Gibco, v/v) and 1% Penicillin/Streptomycin, incubated at 
37 ◦C with 5% CO2 and passaged upon reaching sub-confluency. 
Following seeding at 5000 cells/well in a 96 well plate, the solution 
state or gel state pectin was added after 24 h. Cellular viability was 
assessed using a PrestoBlue™ assay as per manufacturer guidelines. 
Following incubation with cells, PrestoBlue™ was transferred into a 
black 96-well plate and fluorescence measured using a Fluostar Omega 
plate reader (BMG Labtech) at ʎEx 544 nm and ʎEm 590 nm. 
3.1.2. Polymer-only nanoparticle biocompatibility 
Polymer-only NPs were made in sterile conditions. Briefly, 
mPEG5000-PLA100 polymer was dissolved in 1 mL acetone and added 
dropwise to 5 mL PBS, stirring at 550 rpm. Samples were left stirring 
overnight for solvent evaporation. NPs were filtered through a 0.22 μm 
Millex-GV filter and added to astrocytes at a final concentration of 
0.0625 – 1 mg/mL. Viability was measured at 72 h using a PrestoBlue™ 
assay. 
3.2. In vitro pectin degradation 
8 mg gels were incubated in aCSF for up to 28 days at 37 ◦C. At each 
time point, the supernatant was collected and filtered through a Millex 4 
mm, 0.45 µM filter (Sigma Aldrich), before running on Gel Permeation 
Chromatography (GPC). The remaining gel was freeze dried and 
weighed. GPC of the supernatant was carried out using a Wyatt dawn 8 
+ 1200 Infinity series in a system equipped with a Polymer Labs 
aquagel-OH guard column (50 × 7.5 mm, 8 µm) followed by a PL 
aquagel-OH MIXED-H analytical column. Standard Dulbecco’s Phos-
phate Buffered Saline (DPBS) was used as the mobile phase, with a flow 
rate of 1 mL/min. Molecular weight (Mw) was calculated using a Wyatt 
DAWN® HELEOS® II MALS, using a dn/dc of 0.125 mL/g. The resulting 
chromatograms were analysed using ASTRA® software, V.6.1.2.84 
(Wyatt Tech Corp). 
3.3. Bioadhesion study 
Fresh 50 µm rat brain tissue slices were attached to a 20 mm probe 
(top) of a TA-XT plus texture analyser (Stable Micro Systems, UK) using 
double-sided tape. A 200 µM pectin gel was placed onto the stage and 
0.5 N of force applied by the probe for 60 s before lifting at a speed of 
0.5 mm/sec until reaching a height of 10 mm, recording the force 
required to detach the two surfaces. A control sample was used where no 
brain slice was attached to the top probe. 
3.4. Gelling concentration of pectin 
Adapted from Castile et al. [39], solubilised 200 μM pectin and Fast 
green FCF dye was placed into a 3 mL spray bottle with a 50 μL actuator 
and sprayed perpendicularly from 1 cm distance onto a 45◦ angled TLC 
plate which had been soaked for 10 min in 1.5 mM calcium chloride. 
Once sprayed, the plate was left for 5 min before drip length was 
measured. 
3.5. Polymer synthesis 
mPEG5000-PLA100 was synthesised and characterised as per methods 
reported by Phan et al. [45] via PEG-initiated ring-opening polymeri-
zation of lactide block copolymer. Briefly, the desired amount of LA 
(6.94 mmol) and mPEG5000-initiator (0.0694 mmol) were weighed into 
a vial (pre-dried in an oven at 100 ◦C). The [M]:[I] ratio was kept fixed at 
100:1. mPEG5000 and LA were dissolved in 10 mL of dichloromethane in 
a capped vial and the mixture was allowed to fully dissolve at room 
temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (Sigma-Aldrich) was 
then added at 2% (w/w, compared to the monomer; 0.13 mmol), to 
initiate the ring opening polymerization. After 20 min of reaction time 
the polymer was purified via multi-precipitation steps (cold hexane: 
diethyl ether mixture) and dried in a vacuum oven at room temperature 
(25 ◦C) with quantitative conversion of monomer into polymer (from 80 
to 98%). 
3.6. Labelling of mPEG5000-PLA100 with Cy5 
Cy5 was chemically attached to the hydroxyl-terminus of the poly-
mers via disuccinimidyl carbonate (DSC, Sigma-Aldrich) coupling [46]. 
100 mg of polymer (0.005 mmol), 10 µL triethylamine (TEA, 0.07 mmol) 
in 0.5 mL dry acetonitrile (MeCN) and DSC (0.019 mmol) in 1 mL dry 
MeCN was added to a dry glass vial under continuous stirring at 0 ◦C and 
left for 3 h. A stock solution of Cy5-amine (0.002 mmol) and TEA (0.07 
mmol) was prepared in dry MeCN, with Cy5 at 1% (w/w) to the polymer 
and the TEA concentration in excess with respect to the dye. Subse-
quently, 1 mg Cy5 and 10 µL TEA were dissolved in 2 mL dry MeCN. This 
was then added to the reaction under constant stirring at 0 ◦C and left for 
a further 3 h. Finally, the resultant conjugated mPEG5000-PLA100-Cy5 
was purified through multiple precipitation steps in cold hexane: diethyl 
ether mixture. Coupled-Cy5 content was evaluated against Cy5-amine 
standard calibration curve using fluorescence (λex = 647 nm, λem =
665 nm). 
3.7. Nanoparticle manufacture 
Nanocrystals coated with mPEG5000-PLA100 (NCPPs) were prepared 
by a modified method from Styliari et al. [19]. Briefly, 1.25 mg etopo-
side or olaparib were dissolved in 1 mL solvent (acetone, and acetone: 
MeCN:MeOH [1:1:1], respectively) before adding dropwise into 5 mL 
aqueous phase, stirring at 550 rpm. Drug-only nanocrystals were left 
stirring overnight to allow solvent evaporation, before mPEG5000-PLA100 
dissolved in 1 mL acetone was added dropwise into the drug nanocrystal 
aqueous phase whilst stirring. Samples were left stirring overnight to 
allow solvent evaporation before free drug was removed by centrifu-
gation at 10000 × g for 5 min at room temperature (Eppendorf centri-
fuge 5430, Germany). NCPPs were then concentrated with gaseous N2 to 
a predetermined volume and centrifuged again. Polymer-only NPs were 
generated by dissolving polymer in acetone and adding dropwise into 
aqueous phase stirring at 550 rpm. Samples were left overnight for 
solvent evaporation. 
3.8. Transmission electron microscopy (TEM) 
NP structure was analysed by depositing samples onto a graphene 
oxide on Holey Copper 300 mesh (EMResolutions) and analysed using a 
JEOL 2100F TEM operating at 80 kV, equipped with a Gatan Orius CCD. 
3.9. Dynamic light scattering (DLS) 
The diameter (d.nm), polydispersity index (PDI) and zeta potential of 
NPs were determined using a Zetasizer Nano ZS (Malvern Instruments 
Ltd.). A NP dispersion was diluted in Milli-Q water at intensity in the 
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range 104–106 counts/sec and measurements were performed at 25 ◦C 
on a 173◦ backscatter angle. Results are reported as the mean of three 
independent measurements of three different batches (n = 9) ± standard 
error of the mean (SEM). For Zeta potential analysis, NPs were sus-
pended in 10 mM NaCl. 
3.10. NCPP stability 
To determine NCPP stability in different conditions, 0.3 mg/mL 
NCPPs were incubated at a 1:1 ratio with DMEM, aCSF and PBS (n = 3). 
The samples were incubated at 37 ◦C and size measurements of the 
samples were conducted by DLS as previously described above after 1 
and 24 h. 
3.11. Drug loading and drug release 
Drug loading of 1 mg freeze-dried NCPPs was analysed using high- 
performance liquid chromatography (HPLC) (UltiMate 3000, Thermo-
Fisher). A full validation of the HPLC methods was performed in 
accordance with the FDA Guidance for Bioanalytical Method Validation 
[47]. Separation of compounds was achieved on an ACE 5 C18 column 
(250 × 4.6 mm plus an ACE 5 C18 10 × 3 mm guard column) heated at 
40 ◦C. For olaparib, the mobile phase consisted of (10 mM) pH 4 
ammonium acetate/acetonitrile (55/45 v/v) at 1 mL/min for 10 min 
and effluent was monitored at 254 nm [48]. Erlotinib was used as an 
internal standard (IS) at 20 µg/mL and quantitation was achieved by 
measurement of the peak area ratios of olaparib to erlotinib compared to 
a calibration curve. The IS was added to samples in equal amounts and 
therefore corrects for variations in the analyte response caused by 
variability in the sample preparation and analytical procedure; thus it 
allows for more accurate quantification of drug in the sample [49]. 
For etoposide, the mobile phase consisted of (0.5 mM) pH 3.5 formic 
acid/Acetonitrile (65/35 v/v) at 1 mL/min for 10 min and effluent was 
monitored at 220 nm [50]. Erlotinib was used as an IS at 10 µg/mL and 
quantitation was achieved by measurement of the peak area ratios of 
etoposide to erlotinib. Two high, medium and low quality control 
samples were included to check the accuracy of the calibration curve. 
Drug loading was calculated as follows: 
% drug loading =
amount of coated drug (mg)
mass of NP (mg)
× 100 
For drug release, 500 μL concentrated NCPP suspension (±200 μM 
pectin) was added to a 0.5 mL, 3.5 MWCO, slide-a-lyzer cassette con-
taining 14 mL, 10% (w/v) HPβCD and incubated at 37 ◦C. 10% HPβCD 
was chosen due to previous studies reporting solubility of both etoposide 
and olaparib [51,52]. 2 mL samples were taken and replaced (to 
maintain sink conditions) at 0, 0.08, 0.5, 1, 2, 4, 6, 24, 48, 72 and 120 h. 
Samples were filtered through a 0.22 μm Millex-GV filter before running 
on HPLC. 
3.12. Spraying the formulation 
NCPPs at ~0.3 mg/mL in water or PBS as the aqueous phase ±0.5% 
HPβCD (w/v) or 0.5% PF127 (w/v), were added to a 5 mL glass Aptar 
Pharma spray bottle (50 μL actuator). Once sufficiently primed, samples 
were sprayed and collected in an Eppendorf, where they were sized 
using DLS as described above, and compared to a pre-spray control. The 
surfactant/sugar was trialled with the formulation to aid stability of the 
NPs against the shear stress of the spray device. 
3.13. Cy5-labelling of pectin 
100 mg Pectin 101 was dissolved in 10 mL of pure water (1% w/v) 
and allowed to completely solubilize at room temperature under 
continuous stirring. 0.02 mmol Cy5 (2% mol/mol, compared to pectin) 
was dissolved in 1 mL of pure water and added to the cloudy solution of 
pectin. The amount of dye was added to couple approximately 5% of the 
free carboxylic groups alongside the main pectin backbone. Finally, 3 
mL of an aqueous solution of 1-Ethyl-3-(3-dimethylaminopropyl)carbo-
diimide (0.30 mmol, Sigma-Aldrich) was added dropwise to the pectin- 
dye solution. The EDC/Cy5 final molar ratio selected was approximately 
15/1. To the final solution, a catalytic amount of 4-Dimethylaminopyr-
idine was added and the reaction left to stir for 48 h and dialysed against 
pure water for 2 days. 
3.14. In vivo biocompatibility 
7 male CD-1 NuNu mice (10–11 weeks) were purchased from Charles 
River, UK. The experiment was conducted under the UK Home Office 
Licence number PPL P435A9CF8. LASA good practice guidelines, 
FELASA working group on pain and distress guidelines and ARRIVE 
reporting guidelines were also followed. Mice were maintained in 
Individually Ventilated Cages (IVCs) (Tecniplast, UK) within a barriered 
unit illuminated by fluorescent lights set to give a 12 h light–dark cycle 
(on 07.00, off 19.00), as recommended in the United Kingdom Home 
Office Animals (Scientific Procedures) Act 1986. Following a week of 
acclimatisation, the mice were randomly allocated into study groups of 1 
control mouse and 6 experimental mice to receive 200 μM, 3% Cy5- 
labelled pectin (w/w). While under general anaesthesia, a small inci-
sion was made through the skin along the midline of the skull. The 
mouse was secured onto an electronic stereotaxic frame (Harvard 
Apparatus UK) using a nose clamp, and a small burr-hole was drilled 
through the skull, (1 mm to the right of the midline, 1.5 mm anterior to 
the lamboidal suture and 2 mm deep), using a 0.7 mm diameter surgical 
drill bit. A larger drill bit was then used to enlarge the burr hole to 
approximately 1–2 mm. The labelled pectin was then dripped into the 
hole via a pipette and left for one minute, after which time the excess 
was removed with a cotton bud and the process repeated to get the 
maximum volume into the hole. In order to add a larger volume of 
pectin, healthy brain would have had to be removed. The burr hole was 
then plugged with bone wax and the skin sutured shut. The control 
mouse underwent the same surgery without receiving the pectin to 
confirm the procedure itself did not produce (auto)fluorescence. 24 h 
after surgery, the animals were again anaesthetised and imaged. Three 
mice were culled by cervical dislocation and the brains and skulls were 
dissected out and imaged ex vivo (Group 1). Imaging was repeated in the 
remaining mice at 7 days and 14 days (Group 2 plus control). All images 
were collected using the IVIS® Spectrum imaging system, PerkinElmer 
(MA, USA) and analysed using the Living Image software. 
3.15. Haematoxylin and eosin staining 
Mouse brains were fixed in 4% paraformaldehyde and 4 µm sections 
obtained in a series from the surgical boundary. Briefly, sections were 
baked at 60 ◦C overnight and then deparaffinised by submerging the 
slide in xylene three times for 10 min. Slides were treated sequentially in 
100, 95, 80, 70% ethanol, water, Harris haematoxylin and eosin (Sur-
gipath, UK). Stained sections were rehydrated, mounted with DPX 
mounting medium and then observed by light microscopy. 
3.16. Ex vivo analysis of the DDS 
0.3 mg/mL Cy5-labelled polymer-only NPs (to match the final con-
centration of concentrated NCPPs following N2 concentration) were 
sized using a Viscotec and then added to pectin powder to make a 200 
μM solution; 5% PF127 in 0.1 M PBS was then added so that the final 
concentration was 0.5% PF127 and 0.01 M PBS in the formulation. Once 
solubilised via stirring, the sample was added to a 5 mL glass Aptar 
Pharma spray bottle (50 μL actuator) and primed. Ten sprays were 
administered to a 1 cm3 cavity within a fresh porcine cadaver brain 
before sequential biopsies were taken from below the cavity by a 
neurosurgeon. Biopsies were snap frozen and cryosectioned (CM3050 S, 
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Leica, Germany) before analysis using a Zeiss LSM880C Confocal 
Microscope. 
4. Results & discussion 
To determine whether the DDS was suitable for delivery of chemo-
therapeutics for GBM, a hydrogel was trialled for biocompatibility and 
degradation in vitro and in vivo, followed by the development and 
characterisation of drug loaded NPs. These components were tested with 
the commercial spray device and ultimately, trialled in a large ex vivo 
mammalian brain. 
4.1. Pectin degradation in vitro 
The use of a hydrogel in the DDS is hypothesised to prevent the NPs 
being washed away via interstitial fluid and the CSF. However, the 
degradation of pectin within the brain is paramount to allow for elimi-
nation from the brain to reduce any associated side effects. Preliminary 
in vitro tests were conducted to observe if there was any degradation of 
the gels. Pectin gels (200 µM) were incubated in aCSF at 37 ◦C and the 
supernatant collected at various time points and assessed using GPC to 
establish if any pectin had degraded into lower molecular weight 
polymer chains or oligomers. 
Fig. 1. Brain biocompatibility of pectin hydrogel in vitro. (A) Pectin GPC chromatograms following incubation in excess artificial CSF from 1 to 28 days, n = 3. 
(B) U87 cell viability measured using a PrestoBlue™ assay when cells were incubated with 50 µM–200 µM pectin gels at 24 to 72 h, with no significant difference 
observed using a one-way ANOVA with a Dunnett’s post-hoc test when compared to the control, P > 0.05. Results are displayed as mean ± SEM, n = 9. (C) Human 
astrocyte cell viability measured using a RealTime-Glo™ assay when cells were indirectly incubated with 50–200 µM pectin from 1 to 72 h. Results are displayed as 
mean ± SEM, n = 9, with significant reduction in viability determined using a one-way ANOVA with Dunnett’s post-hoc test. (D) Force required on a TA-XT texture 
analyser to remove a rat brain slice from a 200 µM pectin gel, with results displayed as mean ± SD, n = 4. (E) Corresponding image showing bioadhesion of the rat 
brain slice to the pectin gel. (F) Drip lengths of a 200 µM pectin solution sprayed onto TLC plates soaked in d⋅H2O control or 1.5 mM CaCl2. TLC plates were fixed at a 
45◦ angle and the drip length was measured as indicated by the red arrows in the inset image. Results are displayed as mean ± SEM, n = 6, with a significant 
reduction in drip length determined using a one-way ANOVA with Dunnett’s post-hoc test. **** = P < 0.0001. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
P. McCrorie et al.                                                                                                                                                                                                                               
European Journal of Pharmaceutics and Biopharmaceutics 157 (2020) 108–120
113
Fig. 1A shows that the longer the gels were incubated with aCSF, the 
later the pectin eluted from the column, demonstrating a time- 
dependant degradation. Fig. Supplementary Fig. S1 shows the corre-
sponding molecular weights for the peaks in the GPC chromatograms, 
which reveal that over time, the pectin reduced in molecular weight to 
approximately 1.4% of its original weight. Over this period, the 7.9 ±
0.4 mg gels (mean ± SD, n = 18, freeze-dried weight) lost 2.5 ± 0.8 mg, 
also indicating degradation in aCSF. This degradation could be a result 
of the hydrolysis of the cross-linked pectin gel mass into shorter chains 
by the PBS and temperature of incubation [53], hence the reduction seen 
in the Mw from GPC analysis. However, the range of the GPC column 
used is 6000 to 10,000,000 Da. Therefore, the values in Supplementary 
Fig. 1, from day 7 onwards are not reliable, accurate values. Neverthe-
less, these results show that the pectin found within the aCSF had 
considerably degraded from the initial size of 196 kDa within the first 7 
days of incubation. 
It has been reported that natural polyuronates such as pectin and 
alginates are quite resistant and slow to degradation [54]; therefore, 
many studies have investigated enzyme cleavable modifications to the 
pectin chains. One laboratory has developed matrix metalloproteinase- 
cleavable norborene cross-linked pectin gels, which were degraded 
over 9 h in the presence of collagenase type 2 as a function of cross- 
linker density. The authors hypothesised that the cleavage of the cross 
linkers, separating the gel into soluble pectin chains, make them more 
susceptible to the proteolytic environment in vivo. Similarly, Munarin 
et al. generated pectin and RGD-pectin microspheres at 1 g/mL which 
degraded slowly over 24 h in PBS, with the RGD-pectin degrading 
quicker than the non-RGD equivalent [55]. In vivo, it has been shown 
that subcutaneous pectin gels in mice had begun to degrade after one 
week, showing severe fragmentation at 1.5% (w/v) and slight frag-
mentation at 2.5% (w/v) [56]. Collectively, these studies and our data, 
give promise that the pectin should degrade, albeit slowly, in an in vivo 
environment. 
4.2. In vitro biocompatibility of pectin 
Initially four pectin grades were trialled for use with the DDS; as 
shown in Fig. Supplementary Fig. S2, each grade differs by the degree of 
esterification (DE) and hence their calcium reactivity. Exposure to 
pectin 102 and 104 resulted in a reduction in U87 cell viability (chosen 
for preliminary screening, U87 is a robust GBM cell line, therefore any 
reduction of cell viability in this cell line is likely to predict much greater 
sensitivity in healthy cells such as primary human astrocytes) at various 
time points in solution and gel state, likely linked to calcium reactivity 
and the ability of pectin to sequester calcium from the cell medium. 
McKay et al. have investigated the ability of in situ calcium responsive 
hydrogels made of alginate and chitosan to remove calcium from areas 
following acute spinal cord injury (SCI), due to the ability of these 
hydrogels to sequester calcium, which is increased following SCI. They 
found that the elastic modulus of the gel was very sensitive to mM 
changes in calcium concentration, demonstrating an ability to sequester 
calcium ions [57]; thus giving credibility to the theory that high reactive 
pectin gels could be removing vital calcium from the cells. 
Pectin 101 was chosen over pectin 105; although both were 
biocompatible, pectin 101 had a slightly lower DE, which is more cal-
cium reactive and thus appropriate given the low endogenous calcium 
levels within the brain. In vitro biocompatibility analysis of pectin 101 
showed no toxicity in the U87 GBM cell line over 72 h when exposed to 
50 – 200 µM pectin gels (Fig. 1B); however, it did show a concentration 
dependent reduction in human astrocyte metabolic activity when indi-
rectly cultured in pectin medium (Fig. 1C). Astrocytes are the most 
abundant glial cell found within the human brain and were therefore 
chosen to represent ‘healthy’ brain cells. Astrocytes are involved in 
several functions including supporting an intact BBB, regulating water 
and ion homeostasis, in addition to roles within tripartite synapses [58]. 
Following 72 h, the astrocyte viability was 90, 70 and 47% for 50, 
100 and 200 µM pectin concentrations, respectively. Primary astrocytes 
are more sensitive in culture than GBM cell lines [59]. In addition, pectin 
is an anionic polysaccharide with a pKa around 3.5); therefore, pectin 
and its oligomers may reduce the pH of the media, accounting for the 
decrease in cell viability. Goldman et al. found that neurons and glia in 
vitro were sensitive to short incubation times with lactic acid and hy-
drochloric acid, with 1 h incubations in pH 5.2 lactic acid resulting in 
cell death [60]. Hansen et al. similarly found longer exposure times to 
acid, reduced astrocyte cell viability in vitro [61]. This reduction in 
astrocyte viability could also be as a result of the calcium sequestration 
of pectin, as described above. However, due to homeostatic mechanisms 
in vivo, it was assumed that pH and calcium changes due to pectin would 
be reduced in vivo, justifying the continuation of pectin within the DDS. 
4.3. Bioadhesion of pectin gels to brain tissue 
Pectin hydrogels need to be able to adhere to brain tissue in order to 
prevent wash-off of the NPs. Many previous studies have explored the 
bioadhesion of hydrogels to animal tissue by means of a TA-XT texture 
analyser, which analyses the force required to separate two materials 
from one another. In our study, pectin gel bioadhesion to rat brain slices 
showed that when a 0.5 N force for 60 s was applied, there was a sig-
nificant increase in force required to detach the gel from the rat brain 
slice, relative to when no brain slice was present (Fig. 1D). 
The image in Fig. 1E shows the brain attached to the pectin gel as the 
probe moves away. This data demonstrates that when the pectin is 
sprayed into the brain, the gel has the potential to adhere due to the 
bioadhesive forces, instead of being washed away by the interstitial 
fluid. Wattanakorn et al. also studied the bioadhesive nature of low DE 
versus high DE pectin discs on porcine buccal tissue, demonstrating that 
low DE pectin has superior bioadhesive properties; they attributed this 
to the higher hydrophilicity of low DE pectins [62], which has also been 
shown with other hydrophilic polymers in a different study [63]. 
Increased hydrophilicity allows for more hydrogen bonds between tissue 
and pectin gels. Thirawong et al. showed that a higher pH (4.8 versus 
1.2) gave superior adhesion of pectin to gastrointestinal mucosa and 
Markov et al. demonstrated that higher concentrations of pectin resulted 
in greater bioadhesion, resulting from an increased number of sites 
available for hydrogen bonds [64]. All this prior work, including the 
current data, gives promise that pectin could result in suitable bio-
adhesion to hold NPs in place once sprayed into a resection cavity. 
4.4. Gel formation at calcium concentrations found within the brain 
One concern was whether pectin would gel within the calcium 
concentration range (1.5–2 mM) of the brain extracellular space. To 
address this, the pectin solution was sprayed onto TLC plates soaked 
with 1.5 mM of calcium chloride. The gelling capability was measured in 
terms of pectin drip length when sprayed onto a surface at 45◦, which 
was compared to a control solution of water sprayed onto the same 
surface. The drip length was determined from the bottom of the impact 
area to the bottom of the drip, as shown by the red arrows on the inset 
image in Fig. 1F. This methodology was adapted from a study by Castile 
et al. [39], which used the inclined TLC plate method to analyse drip-
ping of pectin-based nasal spray technology. They found a significant 
reduction in drip length when 10 mg/mL LM pectin was used, relative to 
the non-gelling (PBS) control when spraying onto a TLC plate soaked in 
simulated nasal electrolyte solution (CaCl2H4O2 concentration of 4 
mM). 
Similarly, our data shows that there was a significant decrease in drip 
length when a calcium-soaked TLC plate was used instead of a water- 
soaked TLC plate, demonstrating gelling of the 200 μM pectin solution. 
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4.5. In vivo retention and biocompatibility of pectin in a brain resection 
site 
Following promising in vitro results showing a lack of toxicity to U87 
cells, some biocompatibility with primary human astrocytes and signs of 
degradation in aCSF, in vivo retention and toxicological analysis of the 
pectin gel was carried out. To our knowledge pectin has not previously 
been implanted into the brain, despite many other in vivo assessments 
such as the subcutaneous implantation injection of >2.5% (w/v) pectin 
gels in mice, showing no toxicity over 7 days [56]. Therefore, to 
determine whether the pectin gel was fit-for-purpose for the intended 
DDS, it was orthotopically injected into the brains of mice and left for up 
to two weeks. 
Pectin was labelled so that approximately 5% of carboxylic acid 
groups within the pectin backbone would contain a Cy5 label. Pectin 
requires the carboxylic acid groups to gel in the presence of calcium, 
therefore labelling too many of these groups would hinder the gelling 
capability of pectin. This Cy5-pectin powder was combined with non- 
labelled pectin powder at 3% (w/w) which was previously found to 
generate a strong signal using an in vivo Imaging System (IVIS) (data not 
shown). A 200 µM pectin gel was chosen for in vivo analysis as it was 
generally biocompatible in the in vitro analyses. Furthermore, a higher 
concentration of pectin generates a more bioadhesive gel due to the 
ability to form greater hydrogen bonds to brain tissue [64], thus ful-
filling the purpose of the hydrogel (to remain in the tissue it is sprayed 
into). 
Following injection, animals were immediately imaged using the 
IVIS to reveal the location and intensity of the pectin signal and to 
provide a baseline signal. This time point showed maximum baseline 
fluorescence, which could then be tracked over time to show any po-
tential retention or loss of pectin in the brain, directly corresponding to 
Cy5 degradation/elimination. Fig. 2A shows an image from the IVIS of 
animals at 24 h post-pectin injection (with all IVIS images shown in 
Fig. Supplementary Fig. S3). The data in 2B shows that at 24 h, the 
fluorescence observed in ex vivo brains was significantly higher than the 
control baseline signal (sham surgery only), showing good initial 
retention of pectin at the injection site. At day 14, the fluorescence had 
decreased to baseline levels, showing no significant difference between 
the control and the Cy5-pectin injected animals, providing yet further 
evidence that pectin degrades within the brain. 
Over the time course of this experiment, there was no neurotoxicity 
evident in any of the animals; specifically, no weight loss nor behav-
ioural changes were observed, indicating that pectin had not likely 
caused any adverse effects due to exposure within the brain. However, to 
corroborate this evidence, haematoxylin and eosin (H&E) stains were 
carried out on sections of post-sacrificial mouse brains to determine if 
there was any evidence of a local inflammatory response. As shown in 
Fig. 2C, there appears to be no change in local cell morphology or sign of 
an influx of cells indicative of inflammation, compared to the control 
section, at 24 h post-surgery. 
4.6. NCPP structure 
Following the successful determination of a hydrogel fit-for-purpose 
within the brain, we then developed NPs, which would later be held 
within this pectin gel. NPs were developed using a novel method of 
generating drug nanocrystals before coating in a polymeric layer to 
provide a steric barrier. To prove successful coating of the drug 
Fig. 2. In vivo retention and biocompatibility of pectin hydrogel. (A) IVIS image of nude mice following a stereotactic injection of Cy5-labelled pectin into the 
brain. Image taken at 24 h following surgery. (B) Ex vivo Cy5 fluorescence detected in the brains by the IVIS. Retention was shown at 24 h with a significant reduction 
in fluorescence observed at 14 days following surgery when using a one-way ANOVA with Dunnett’s post-hoc test when compared to the control animal. ** = P <
0.01. (C) Haematoxylin and Eosin stained brain sections from (i) sham surgery control animal and (ii, iii) pectin injected animals, sacrificed at 24 h post-surgery, 
showing no difference in cellular morphology relative to sham surgery controls. 
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nanocrystals, TEM and DLS were used. Prior to adding a polymer 
coating, the drug nanocrystal had a z-average between 100 and 300 nm 
with variable and multiple peaks observed within samples, and with 
large PDI values (>0.3). As shown in Fig. 3A, etoposide nanocrystals at 
0.25 mg/mL, had an average size of 112 nm and a PDI of 0.345, with 
large error bars showing differences between individual samples; how-
ever, when coated with 0.25 mg/mL polymer, this reduced to 68 nm and 
a PDI of 0.232. This was also observed for olaparib nanocrystals, which 
showed clear aggregates that were not present when there was polymer 
in the formulation (Fig. 3B). This suggests that there could be some 
solvent-nanocrystal and drug-polymer interactions occurring, which 
may have caused the drug to disaggregate, allowing the formation of a 
smaller, coated NP [19]. 
From TEM images, nanocrystals, when compared to NCPPs, reveal 
visible differences in structure, providing evidence for NCPPs (rather 
than two distinct populations). Fig. 3C shows both etoposide and ola-
parib NCPPs were visibly different from the larger and heterogeneously 
sized drug nanocrystals. The NCPPs had a double shell structure, with 
the core exhibiting a lower contrast than the shell, thus giving evidence 
for true polymer-coated drug NPs (more representative TEM images can 
be seen in Fig. Supplementary Fig. S4). Further comparisons of zeta 
potential (ZP) data from drug nanocrystals and polymer-only NPs, 
compared to NCPPs corroborate TEM and DLS results. The ZP curves 
reveal multiple peaks for non-coated drug nanocrystals, which shifts to 
the same value as the polymer control when the drug was coated 
(Fig. 3D-E). A recent publication by Styliari et al., suggested very similar 
results when coating indomethacin with a PEG-polycaprolactone 
diblock copolymer. Although the methodology to generate the NCPPs 
was different (flow nanoprecipitation), the study also found differences 
in DLS and TEM data, before and after coating with amphiphilic poly-
mer. The report suggested that the addition of the solvent/polymer may 
have broken up larger drug aggregates, allowing the coating of smaller 
individual drug NPs [19], which supports our findings. 
Fig. 3. Size distribution profiles and visualisation of NCPPs. (A) DLS curves of 0.25 mg/mL etoposide pre- (112 ± 16 nm, PDI: 0.345 ± 0.196) and post-coating 
with 0.25 mg/mL mPEG5000-PLA100 (68 ± 2 nm, PDI: 0.232 ± 0.044), and (B) 0.25 mg/mL olaparib pre- (136 ± 19 nm, PDI: 0.393 ± 0.221) and post-coating with 
0.25 mg/mL mPEG5000-PLA100 (67 ± 1 nm, PDI: 0.194 ± 0.017). Results are shown as mean ± SD, n = 3. (C) TEM images taken at 20,000× magnification of: i) 0.25 
mg/mL etoposide in water; ii) 0.25 mg/mL etoposide NCPPs; iii) 0.25 mg/mL olaparib in water; iv) 0.25 mg/mL olaparib NCPPs. Scale bar = 100 nm. (D) Zeta 
potential of 0.25 mg/mL etoposide NCPPs and (E) 0.25 mg/mL olaparib NCPPs versus polymer-only and drug-only controls. Results are shown as mean ± SD, n = 3. 
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4.7. NCPP stability and drug release 
The stability of NCPPs was then studied in different aqueous media at 
37 ◦C for up to 24 h. Fig. 4A shows the etoposide NCPPs in PBS, DMEM 
and aCSF, confirming high stability at 24 h. The PDI of all samples did 
not significantly increase over the time course, representing a mono-
disperse system. Fig. 4B shows the same results for olaparib NCPPs, 
whereby there was no significant increase in size nor PDI up to 24 hrs. 
Previous work showed stability of these PLA-PEG based NPs when 
incubated with bovine serum albumin, displaying their ability to resist 
any protein-induced aggregation; the study also demonstrated NP sta-
bility to increasing NaCl concentrations [45] and although these were 
polymer-only NPs, this indicates inherent high stability of these NPs. 
Initial drug loading of the NCPPs was 32% and 33% for etoposide 
and olaparib, respectively. These NCPPs were then subjected to 
increased concentrating via N2 gas evaporating off the aqueous phase. 
Final HPLC of these NCPPs showed an absolute drug concentration of 
0.30 ± 0.01 mg/mL and 0.24 ± 0.05 mg/mL (mean ± SD, n = 3), for 
etoposide and olaparib NCPPs, respectively. For etoposide, this level of 
drug loading exceeds that shown in the majority of previous studies; for 
PEG-PLA based NPs, a drug loading of 9.6% has been shown [65]; 
however a study by Saadati et al. [66] reported drug loading which was 
dependent on the method of NP preparation where PLGA-PEG NPs 
generated by nanoprecipitation had an etoposide drug loading of 7% 
and those generated by solvent evaporation had a drug loading of 12%. 
This distinct methodology could be one factor which has led to the high 
drug loading of these polymer NPs. This is also corroborated by Styliari 
et al., having demonstrated a drug loading of 78% for indomethacin 
using a similar coating strategy [19]. For olaparib, there are few poly-
meric NPs reported in the literature. Wu et al. [67] manufactured PEG- 
poly e-caprolactone NPs with an olaparib drug loading as high as 10%; 
however, to the best of our knowledge, no PLA-PEG based olaparib NPs 
have been reported. 
Drug release was analysed over 120 h with the results in Fig. 4C and 
D displaying that release from the concentrated NCPPs was rapid, with a 
burst release of 5% for olaparib in the first 30 min followed by 85% after 
24 h. Likewise, for the etoposide sample, there was a burst of 9% in the 
first 30 min followed by 83% after 24 h. In both cases, 100% drug release 
was released after 48 h. However, when the NCPPs were incubated with 
pectin, 20% of olaparib seemed to be trapped within the hydrogel. This 
was likely a result of hydrophobic interactions between the esterified 
regions of the pectin gel and olaparib molecules [68]. Rapid release of 
drug from these NPs means that the drug may potentially be released 
immediately post-surgery, at a time when there is the lowest residual 
tumour burden within the brain. Following maximal surgical resection, 
there are few cells left within the healthy brain tissue and therefore 
targeting these cells before rapid proliferation and bulk tumour recur-
rence is likely to generate higher efficacy of the chemotherapies. 
Fig. 4. In vitro characterisation and release profiles for drug-loaded polymeric nanoparticles. Size and PDI of (A) etoposide and (B) olaparib NCPPs following 
incubation with PBS, DMEM and aCSF at 1 and 24 h. No dilution of NCPPs was necessary for the DLS measurements. Results displayed as mean ± SEM, no sig-
nificance was found in a one-way ANOVA with a Dunnett’s post-hoc test, when compared to the control, n = 3. (C) Drug release into 10% w/v HPßCD in water from 
etoposide NCPPs and (D) olaparib NCPPs ± 200 µM pectin gel over 120 h at 37 ◦C, showing 9% and 5% release in the first 30 min followed by 85% and 83% after 24 
h for etoposide and olaparib, respectively. Results are displayed as mean ± SD, n = 4. 
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4.8. Biocompatibility of NPs with astrocytes 
Biocompatibility of the DDS is paramount for successful use within 
the brain; therefore, biocompatibility of polymeric NPs with ‘healthy’ 
matter within the brain was studied by incubating 0.0625 to 1 mg/mL 
NPs (no drug) with human astrocytes. Fig. Supplementary Fig. S5 shows 
that there was no significant reduction in astrocyte viability over 72 h at 
any concentration. These results were anticipated due to the plethora of 
literature showing good biocompatibility of PLA-PEG based NPs 
[25–27]. 
Characterisation of these NCPPs established that they were fit-for- 
purpose for the DDS under development, henceforth they, alongside 
the pectin hydrogel, were trialled with the spray device. 
Fig. 5. In vitro spray characterisation of pectin and drug-loaded nanoparticles. (A) Image showing the successful spray mist, with the inset image showing the 
spray pattern. (B) DLS curves of 0.25 mg/mL olaparib NCPPs in water pre- (68 ± 3 nm, PDI: 0.236 ± 0.089) and post-spray (69 ± 2 nm, PDI: 0.236 ± 0.102), with 
results displayed as mean ± SD, n = 4. (C) DLS curves of 0.25 mg/mL olaparib NCPPs in 0.01 M PBS pre- (109 ± 4 nm, PDI: 0.256 ± 0.011) and post-spray (236 ±
201 nm, PDI: 0.400 ± 0.097), with results shown as mean ± SD, n = 4. (D) Bar chart showing size and PDI values of 0.25 mg/mL etoposide and olaparib NCPPs in 
0.01 M PBS and 0.5% w/v PF127, pre- and post-spray. Results are displayed as mean ± SD, n = 3. No significance between pre- and post-spray was found when using 
a two-tailed t test. (E) Drip lengths of a 200 µM pectin solution ± polymer-only NPs pr NCPPs sprayed onto TLC plates soaked in 1.5 mM CaCl2. TLC plates were fixed 
at a 45◦ angle and the drip length was measured. Results are displayed as mean ± SEM, n = 6, with a significant reduction in drip length determined using a one-way 
ANOVA with Dunnett’s post-hoc test. * = P < 0.05. 
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4.9. Spraying of the formulation 
Successful spraying of the viscous hydrogel solution is shown in 
Fig. 5A, whereby a 200 µM pectin gel with a blue dye shows the spray 
pattern when 50 µL was sprayed. Fig. Supplementary Fig. S6 shows the 
volumes per spray from the device, demonstrating consistent and correct 
volumes sprayed. This device was then trialled with the NPs in solution. 
As shown in Fig. 5B, when a solution of olaparib NCPPs in milliQ water 
aqueous phase plus 0.5% HPβCD to aid stability, was sprayed, there was 
no change in NP size nor appearance of a second peak indicative of 
aggregation. This data was the same for etoposide NCPPs 
(Fig. Supplementary Fig. S7). However, when introducing PBS into this 
aqueous phase (Fig. 5C), the results showed that the NPs aggregated, 
despite the HPβCD sugar presence in the formulation. 
The steric barrier of the polymer is clearly sufficient at preventing 
NCPP aggregation, as previously shown in the PBS samples in Fig. 4A 
and B. However, when the NCPPs are subjected to shear stress when 
forced through the spray nozzle, the polymeric layer may not be able to 
overcome the reduced dispersion of NPs within the small droplet volume 
of the spray mist, nor the attractive Van der Waals forces and the 
reduced electric double-layer repulsion when PBS is present [69–72], 
thus likely leading to aggregation. A paper by Hendriks et al., showed 
how cell viability decreased when spray pressure increased. The reduced 
viability was proposed to be as a result of smaller spray droplets being 
formed due to this increase in pressure. These smaller drops impacted 
with the surface at higher velocities, which led to increased cell defor-
mation and thus cell death [73]. Although cells are very different to our 
application, the concept is the same for NPs. With increasing pressure 
(and shear stress), the spray droplets formed will be smaller, causing a 
reduction in the dispersion of the NPs within this droplet. This, along-
side the impact speed from increased pressure, is likely to deform and 
aggregate the NPs. Furthermore, a study by Jeong et al. [74] commented 
on adhesive mussel-protein based NPs for locoregional cancer therapy, 
and their stability to spray, which the authors attributed to the low PBS 
concentration and ethanol content (30:70 v/v). The study suggests high 
dispersion of NPs is key to successful spraying, as low dispersion of NPs 
allows aggregation when the NPs pass through the nozzle. In this 
instance, the low PBS concentration allowed electrostatic repulsion of 
the NPs, and the low surface tension of ethanol removed chances of 
aggregation. However, such a high ethanol concentration would likely 
prove toxic to the human brain; high concentrations of ethanol in the 
brain make it vulnerable to ethanol-induced reactive oxygen species 
(ROS) due to its high content of peroxidable fatty acids [75,76] and 
therefore it was not suitable for use in this application. 
It could not be determined whether the viscous pectin solution 
enhanced survival of the NCPPs as pectin sequesters the NCPPs, which 
rendered them being undetectable on the DLS. The solution state pectin 
was also unstable when imaged using TEM, meaning conclusive evi-
dence could not be gathered for NCPP survival. Therefore, we explored 
the addition of a surfactant in the aqueous phase. 
PF127 was then added to the formulation instead of HPβCD, to assess 
if this provided stabilising properties when PBS was present in the 
formulation. PF127 is FDA approved and has been widely used in vivo 
due to its relatively non-toxic and biodegradable properties [77]. Pre-
vious studies have reported PF127 gel use within the brain up to 18% 
(w/v) with no associated side effects [78,79]. Other formulations have 
used PF127 between 0.13 and 13% (w/v) to stabilise silver NPs [80] and 
shown that Pluronics (F127 and F108) provide greater steric stability to 
PLGA-NPs. The Pluronics made the system less sensitive to increases in 
ionic strength, proven by the increased critical aggregation concentra-
tion [81]; therefore PF127 was tested within our system. A 5% PF127 
solution in 0.1 M PBS (w/v) was added to the NCPP formulation, 
generating a final concentration of 0.5% PF127 and 0.01 M PBS. The 
results are shown in Fig. 5D, showing no significant change in NP size 
nor PDI following spraying. 
We have so far demonstrated that pectin gelled in the presence of 
calcium concentrations equivalent to those found within the brain. 
However, we also wanted to assess any changes brought about by NPs or 
NCPPs within the pectin formulation. Therefore, to assess the effects of 
polymer-only NPs and NCPPs on the ability of pectin to gel, pectin so-
lution with and without NPs was sprayed onto an inclined TLC plate 
soaked in 1.5 mM CaCl2 (as before). As shown in Fig. 5E, there was a 
significant (P < 0.05) reduction in drip length of 200 μM pectin when in 
the presence of NPs or NCPPs. There was no difference between the two 
NP formulations (with or without drug), which was anticipated due to 
the drug residing in the centre of the NCPP, thus not interacting with the 
pectin medium. A change in viscosity between the pectin control and 
pectin with NPs was anticipated as it has previously been demonstrated 
that a hydrogel in the presence of NPs exhibits different physio-chemical 
properties as a result of non-covalent interactions [82]. It is likely that 
the non-covalent interactions between the NPs and hydrogel have 
increased the viscosity of the formulation, thus reducing the measured 
drip length. 
4.10. Application of the DDS to a large mammalian brain 
Following the completion of hydrogel and NCPPs characterisation 
with the spray device, the DDS was trialled in an ex vivo porcine brain, 
representative of a large mammalian brain to show if the DDS was fit- 
for-purpose. In this experiment, Cy5-labelled polymer-only NPs were 
trialled in the brain for confocal microscopy analysis. No drug was 
present within the NPs in order to simplify the detection of the NPs 
within brain tissue. Despite the lack of drug in the NP, this work still 
presents the benefit of spraying the optimal formulation into a resection 
cavity. 
Pectin (200 µM) with Cy5 labelled NPs at equal size to the NCPPs (70 
± 15 nm [mean ± SD, n = 15]) was sprayed into the linings of a surgical 
pseudo-resection cavity and sequential biopsies taken from below this 
cavity to determine successful delivery of the system and assess depth of 
penetration. Confocal microscopy shown in Fig. 6 displayed NP presence 
in the biopsy tissue up to 1.5 cm deep. As the study by Nance et al. 
suggests, this result was anticipated due to the size (70 nm) and PEGy-
lation (mPEG5000) of the NPs, conferring decreased interactions with 
brain tissue [11] and confirming our DDS design. From the confocal 
images, it seems that there is a greater accumulation of fluorescence 
observed in biopsy 3. It would be anticipated that the greatest fluores-
cence seen would be in biopsy 1 due to the site of application however, 
this depends on the area and the orientation of the biopsy which has 
been sectioned. For biopsy 3, there could have been a reservoir of NPs 
which had built up due to a white matter tract leading to this area, and 
we could also have sectioned a tissue region which contained more NPs, 
relative to other regions. Nevertheless, this technique was a qualitative 
means to determine NP penetration in a large mammalian brain, 
showing high success of NP translocation post-spray into a surgical 
cavity. 
5. Conclusion 
A DDS has been developed which uses a spray device to successfully 
deliver a bioadhesive hydrogel and high etoposide and olaparib loaded 
polymeric NPs to a surgical resection site. Pectin solution can be sprayed 
successfully, and it has proven to be bioadhesive and which gels in the 
presence of calcium concentrations found locally within the brain. To 
our knowledge, this is the first report to show biocompatibility within 
the brain in vivo, with no neurotoxicity in animals observed over two 
weeks. We have developed two novel polymer-coated nanoparticle 
formulations at ~70 nm, with drug concentrations of 0.30 and 0.24 mg/ 
mL for etoposide and olaparib respectively. These NCPPs are stable in 
different media such as aCSF, DMEM and PBS, can survive the shear 
stress of a spray device and release therapeutic cargo rapidly over 48 h. 
We have demonstrated clinical utility of this DDS via NP delivery within 
a surgical pseudo-resection cavity in large mammalian brain, revealing 
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the presence of NPs in the surrounding tissue up to 1.5 cm away from the 
cavity. Our data collectively demonstrates the pre-clinical development 
of a novel DDS based on a sprayable hydrogel containing therapeutic 
NCPPs, which is amenable for translation to orthotopic brain tumour 
surgical resection models to assess efficacy upon localised delivery. 
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